ELRIG Announces Speaker Programme for Drug Discovery 2012 Conference
News Apr 30, 2012
During the event, scientists engaged in early-phase drug discovery, whether from academia, biotech or industry, will have a chance to network and meet with a wide selection of vendors during the exhibition which features over 100 booths, an Innovation Zone, Media Area and Careers Zone.
A programme of scientific sessions will feature presentations from a range of academic and industry leaders in their fields, including the following keynote speakers:
• Chris Lipinski, Massechusetts University (Assay Development and Screening)
• Rod Hubbard, Vernalis (Fragment Discovery for Enzyme & Membrane Targets)
• Michael Schneider, Imperial College London (Primary Cells & Stem Cells in Discovery)
• John Mayer, Nottingham University (Ubiquitin Cascade Biology & Drug Discovery)
• Speaker to be confirmed (Advances in Liquid Handling & Detection Technologies)
• Joerg Heuser, Bayer (Compound Collection Management & Enhancement)
• Nessa Carey, Pfizer (Epigenetics Drug Discovery)
• Manfred Auer, Edinburgh University (Biophysics & Label Free Detection Technologies).
New at this year’s event is a Lunchtime Seminar: in collaboration with SLAS, titled ‘Informatics: Making Knowledge from Laboratory Data’. The presentations will be complemented by a poster session, and a number of vendor training sessions.
At this year’s event, students, graduates and post-docs are again invited to compete for the SLAS Young Scientist Award by submitting a poster at the conference. The winner, selected by a panel of judges including scientists, ELRIG and SLAS personnel, will be invited to present and participate in the Student Poster Competition at the SLAS2013, in Orlando, FL, USA, 12-16 January 2013. SLAS Young Scientist Award winners receive a $500 cash prize, roundtrip airfare, hotel accommodation and conference registration for SLAS2013.
Cancer Gene Plays Key Role in Cystic Fibrosis Lung InfectionsNews
Recent findings explain why people with cystic fibrosis are particularly prone to respiratory infections—and suggest a new approach to treatment.READ MORE
Oligonucleotide Drug Producers Report on Drug ImpuritiesNews
A new addition to a series of articles that focus on important topics related to the development of oligonucleotide therapeutics presents an in-depth look at the identification, characterization, and reporting of product-related impurities.READ MORE